Home » Topics » Regulatory » EMA

EMA
RSS

E.U. orphan drug status recommended for ALN-TTR01 in familial amyloidotic polyneuropathy

Jan. 27, 2011

CHMP recommends approval of Pravafenix

Jan. 26, 2011

CHMP recommends new indications of INOmax

Jan. 25, 2011

CHMP recommends European marketing authorization for Trobalt

Jan. 25, 2011

CHMP issues positive opinion on Eisai's Halaven for metastatic breast cancer

Jan. 25, 2011

CHMP decides against approval of Fampyra to improve walking in MS

Jan. 24, 2011

CHMP recommends approval of Jevtana combination regimen for prostate cancer

Jan. 24, 2011

CHMP adopts final negative opinion for cladribine tablets in relapsing-remitting MS

Jan. 24, 2011

CHMP adopts positive opinion for Gilenya in relapsing-remitting MS

Jan. 24, 2011

CHMP issues positive opinion on European orphan drug status for darinaparsin in PTCL

Jan. 21, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...